Print Friendly, PDF & Email


HLA-DR PE


Catalogue number: 0DR4

Synonyms
HLA-DR* PE

Clone423L
IsotypeIgG2a
Product Type Single-Color Reagent
Units100 Tests
HostMouse
Application Flow Cytometry
Product Form
RPE

Background
HLA-DR is used for the identification of human B cell and T cell subsets associated with approximately 10% of peripheral blood lymphocytes 28-34,000 M.W. surface antigen, and is present in low density on monocytes and macrophages.

Immunogen
HLA-DR=Derived from the hybridization of mouse NS-1/1-Ag4 myeloma cells with spleen cells of BALB/c mice immunized with human lymphoblastoid B-cell line RPMI 8866

Purification Method
Protein A/G Chromatography

Concentration
Titered for flow cytometry

Formulation
Provided as solution in phosphate buffered saline with 0.08% sodium azide and 0.2% carrier protein

Functional Analysis
Flow Cytometry Staining

Applications
PBMC: Add 10 µl of MAB/10^6 PBMC in 100 µl PBS. Mix gently and incubate for 15 minutes at 2º to 8ºC. Wash twice with PBS and analyze or fix with 0.5% v/v of paraformaldehyde in PBS and analyze. WHOLE BLOOD: Add10 µl of MAB/100 µl of whole blood. Mix gently and incubate for 15 minutes at room temperature 20ºC. Lyse the whole blood. Wash once with PBS and analyze or fix with 0.5% v/v of paraformaldehyde in PBS and analyze. See instrument manufacturer’s instructions for Lysed Whole Blood and Immunofluorescence analysis with a flow cytometer or microscope.

Storage
Product should be stored at 4-8ºC. DO NOT FREEZE

Ship Conditions
room temperature

Product Stability
Reagents are stable for the period shown on the vial label when stored properly

References
1. IL-4 and granulocyte-macrophage colony-stimulating factor selectively increase HLA-DR and HLA-DP antigens but not HLA-DQ antigens on human monocytes. Gerrard T.L., Dyer D.R., Mostowski H.S., J. Immunol. 1990 June, 1;144(12): 4670-4. 2. Structural requirements for pairing of alpha and beta chains in HLA-DR and HLA-DP molecules. Karp D.R., Teletski C.L., Jaraquemada D., Maloy W.L., Coligan J.E., Long E.O., J. Exp.. Med. 1990 March ;171(3):615-28. 3. Trans-activation of HLA-DR gene by hepatitis B virus X gene product. Hu K.Q., Vierling J.M., Siddiqui A., Proc. Natl. Acad. Sci. USA 1990 SEPT.; 87(18):7140-4. 4. Purified primitive human hematopoietic progenitor cells with long-term in vitro repopulating capacity adhere selectively to irradiated bone marrow stroma. Verfaillie C., Blakolmer K., McGlave P., J. Exp. Med. 1990 Aug.: 172(2):509-2. 5. Defective clonogenic potential of CD8+ T lymphocytes in patients with AIDS. Expansion in vivo of a nonclonogenic CD3+ CD8+ DR+ CD25- T cell population. Pantaleo G., Keonig S., Baseler M., Lane H.C., Fauci A.S., J. Immunol. 1990 Mar ; 144(5):1696-704. 6. Increased circulating HLA-DR+ CD4+ T cells in systemic lupus erythematosus: alterations associated with prednisolone therapy. Raziuddin S., Nur M.A., al-Wabel A.A., Scand. J. Immunol. 1990 Feb.:31(2):139-45.

Caution
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals.

Safety Datasheet(s) for this product:

Sodium Azide
/wp-content/uploads/2018/07/Antibody-SDS-with-Sodium-AzideV2.pdf

HLA-DR PE

$191.00


Brand

Contact us

Exalpha Biologicals, Inc.
2 Shaker Road, Unit B101
Shirley, MA 01464
Phone: 978-425-1370
Email: info@exalpha.com

Newsletter







Member